Antipsychotic Switching in Bipolar Disorder with Metabolic Comorbidities: A Case Report
DOI:
https://doi.org/10.61194/psychology.v3i3.782Keywords:
Bipolar Disorder, Antipsychotic switching, Clozapine, Quetiapine, Metabolic complicationsAbstract
Bipolar disorder is a chronic psychiatric condition marked by alternating episodes of mania, hypomania, and depression, often with psychotic features. Treatment resistance and adverse metabolic effects from long-term antipsychotic use pose significant challenges. This case report presents a 31-year-old male in Indonesia with bipolar disorder and metabolic comorbidities, including type 2 diabetes mellitus and dyslipidemia. Initially treated with clozapine, the patient experienced metabolic decompensation, prompting an urgent switch to quetiapine. Post-switch, he exhibited improved mood stability and remission of psychotic symptoms, though residual depressive symptoms persisted. Lithium and sertraline were introduced to address these, with careful monitoring. The case highlights the importance of individualized switching strategies in bipolar disorder, particularly in patients with metabolic risks. Antipsychotic selection should consider both psychiatric efficacy and metabolic safety. Despite pharmacological improvement, functional recovery was incomplete, emphasizing the role of psychosocial interventions and culturally informed care. The integration of religious values and family support proved essential in this context. Although effective in symptom stabilization, the switch strategy remains limited by the lack of long-term follow-up and generalizability. This report underscores the need for structured protocols for antipsychotic switching and holistic treatment models, especially in resource-limited settings. Future research should explore integrative approaches that address both psychiatric and physical health dimensions, ensuring continuity of care beyond pharmacological intervention.
References
Abdillah, Y. N., Algristian, H., & Azizah, N. A. S. (2022). Islamic principles in mental medicine. Jurnal Medis Islam Internasional, 3(2), 56–64. https://doi.org/10.33086/iimj.v3i2.2240
Bartoli, F., Cavaleri, D., Nasti, C., Moretti, F., Crocamo, C., & Carrà, G. (2023). Long-acting injectable antipsychotics for the treatment of bipolar disorder: Evidence from mirror-image studies. Therapeutic Advances in Psychopharmacology, 13, 20451253231163680. https://doi.org/10.1177/20451253231163682
Bernardo, M., Rico-Villademoros, F., García-Rizo, C., López-Muñoz, F., & Vieta, E. (2021). Real-world data on the adverse metabolic effects of second-generation antipsychotics and their potential determinants in adult patients: A systematic review of population-based studies. Advances in Therapy, 38(5), 2491–2512. https://doi.org/10.1007/s12325-021-01689-8
Calkin, C. V, Velde, C., & Rybakowski, J. K. (2022). Metabolic psychiatry: An update on metabolic comorbidity and potential mechanisms linking mood disorders and metabolic dysfunction. Molecular Psychiatry, 27(2), 859–873. https://doi.org/10.1038/s41380-021-01176-5
Chaudhuri, K. R., Tolosa, E., Antonini, A., & Martinez‐Martin, P. (2023). Neuroprotective and anti-inflammatory roles of GLP-1 agonists: Relevance for mood and metabolic disorders. European Neuropsychopharmacology, 60, 1–13. https://doi.org/10.1016/j.euroneuro.2023.03.004
Colom, F., Vieta, E., Martínez-Arán, A., Reinares, M., Goikolea, J. M., & Benabarre, A. (2003). A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Archives of General Psychiatry, 60(4), 402–407. https://doi.org/10.1001/archpsyc.60.4.402
Correll, C. U., Detraux, J., Lepeleire, J., & Hert, M. (2015). Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry, 14(2), 119–136. https://doi.org/10.1002/wps.20204
Delgado, A., Velosa, J., Zhang, J., & Berk, M. (2020). Clozapine in bipolar disorder: A systematic review and meta-analysis. Journal of Psychiatric Research, 125, 21–27. https://doi.org/10.1016/j.jpsychires.2020.02.026
Fornaro, M., Berardis, D., Perna, G., Valchera, A., Vancampfort, D., Solmi, M., Veronese, N., & Stubbs, B. (2020). The concept and management of acute episodes of treatment-resistant bipolar disorder: A systematic review and exploratory meta-analysis of randomized controlled trials. Journal of Affective Disorders, 277, 107–118. https://doi.org/10.1016/j.jad.2020.07.109
Gitlin, M. (2016). Lithium side effects and toxicity: prevalence and management strategies. International Journal of Bipolar Disorders, 4(1). https://doi.org/10.1186/s40345-016-0068-y
Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016). Bipolar disorder. The Lancet, 387(10027), 1561–1572. https://doi.org/10.1016/S0140-6736(15)00241-X
Kang, M. G., Qian, H., & Keramatian, K. (2020). Lithium vs valproate in the maintenance treatment of bipolar I disorder: A post-hoc analysis of a randomized double-blind placebo-controlled trial. Australian & New Zealand Journal of Psychiatry, 54(1), 52–60. https://doi.org/10.1177/0004867419894067
Koenig, H. G. (2012). Religion, Spirituality, and Health: The Research and Clinical Implications. ISRN Psychiatry, 1–33. https://doi.org/10.5402/2012/278730
Maj, M. (2011). Is it possible to explain complex mental disorders at the biological level? World Psychiatry, 10(1), 1. https://doi.org/10.1002/j.2051-5545.2011.tb00001.x
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., & Singh, A. B. (2021). The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Australian & New Zealand Journal of Psychiatry, 55(1_suppl), 7–117. https://doi.org/10.1177/0004867420979353
Miklowitz, D. J. (2008). Adjunctive psychotherapy for bipolar disorder: State of the evidence. American Journal of Psychiatry, 165(11), 1408–1419. https://doi.org/10.1176/appi.ajp.2008.08040488
Miskowiak, K. W., Burdick, K. E., Martinez-Aran, A., Bonnin, C. M., Bowie, C. R., Carvalho, A. F., & Vieta, E. (2023). Cognitive impairment in bipolar disorder: Towards a precision psychiatry approach. Biological Psychiatry, 93(6), 500–511. https://doi.org/10.1016/j.biopsych.2022.08.029
Pacchiarotti, I., Mazzarini, L., Colom, F., Sanchez-Moreno, J., Girardi, P., & Vieta, E. (2013). Treatment of acute bipolar depression: A systematic review and meta-analysis. Acta Psychiatrica Scandinavica, 127(6), 405–413. https://doi.org/10.1111/acps.12088
Pillinger, T., McCutcheon, R. A., Vano, L., Mizuno, Y., Arumuham, A., Hindley, G., & Howes, O. D. (2020). Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, bipolar disorder, and other diagnoses: A systematic review and network meta-analysis. The Lancet Psychiatry, 7(1), 64–77. https://doi.org/10.1016/S2215-0366(19)30416-X
Ratheesh, A., Hett, D., Ramain, J., & Scott, E. M. (2023). A systematic review of interventions in the early course of bipolar disorder I or II: A report of the International Society for Bipolar Disorders Taskforce on early intervention. International Journal of Bipolar Disorders, 11(1), 2. https://doi.org/10.1186/s40345-022-00275-3
Vancampfort, D., Wampers, M., Mitchell, A. J., Correll, C. U., Herdt, A., Probst, M., & Hert, M. (2015). A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry, 14(3), 339–352. https://doi.org/10.1002/wps.20252
Vieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., & Yatham, L. N. (2022). Bipolar disorders. European Neuropsychopharmacology, 56, 1–26. https://doi.org/10.1016/j.euroneuro.2021.10.003
Yatham, L. N., Kennedy, S. H., Parikh, S. V, Schaffer, A., Bond, D. J., Frey, B. N., & Vieta, E. (2023). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2023 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 25(2), 123–155. https://doi.org/10.1111/bdi.13253
